IO Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

IO Biotech şirketinin toplam hissedar öz sermayesi $72.6M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $89.9M ve $17.4M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$80.19m
Eşitlik	US$72.57m
Toplam yükümlülükler	US$17.38m
Toplam varlıklar	US$89.95m

Son finansal sağlık güncellemeleri

Recent updates

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 12

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 10

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jun 15

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Jan 20

IO Biotech names new CFO

Oct 13

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Sep 27

IO Biotech GAAP EPS of -$0.64

Aug 11

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Jun 14

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Feb 25

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: IOBT 'nin kısa vadeli varlıkları ( $86.2M ) kısa vadeli yükümlülüklerini ( $16.1M ) aşıyor.

Uzun Vadeli Yükümlülükler: IOBT şirketinin kısa vadeli varlıkları ( $86.2M ) uzun vadeli yükümlülüklerini ( $1.3M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: IOBT borçsuzdur.

Borcun Azaltılması: IOBT un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: IOBT şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: IOBT un, serbest nakit akışı her yıl % 36.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

IO Biotech Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

Recent updates

IO Biotech, Inc. Announces Data from the NSCLC Cohort in the Phase 2 Basket Trial of IO102-IO103

IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-Line Treatment of Advanced Head and Neck Cancer

Price target decreased by 13% to US$8.50

IO Biotech, Inc. Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma

New major risk - Financial position

New minor risk - Share price stability

We're A Little Worried About IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech, Inc. Announces Resignation of Jack Nielsen as Member of the Board of Directors

IO Biotech, Inc., Annual General Meeting, Jun 06, 2024

New minor risk - Market cap size

IO Biotech Announces Marjan Shamsaei as Senior Vice President

IO Biotech, Inc. Presents New Data At Aacr 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, Io102-Io103

IO Biotech, Inc. Appoints Faiçal Miyara as Chief Business Officer

IO Biotech Announces Acceptance of Abstract to Be Presented at the 2024 American Association for Cancer Research Annual Meeting

New major risk - Revenue and earnings growth

New minor risk - Market cap size

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech Announces First Patient Dosed in Phase 2 Neoadjuvant/Adjuvant Solid Tumor Basket Trial

High number of new directors

IO Biotech Appoints Helen Collins, Md, to Its Board of Directors

IO Biotech Completes Enrollment of 380 Patients in Pivotal Phase 3 Trial in Advanced Melanoma

New minor risk - Share price stability

New major risk - Revenue and earnings growth

New major risk - Shareholder dilution

Price target decreased by 15% to US$9.67

IO Biotech, Inc. Appoints Heidi Hunter to Its Board of Directors

IO Biotech, Inc. announced that it expects to receive $75.057935 million in funding from a group of investors

IO Biotech Announces First Patient Dosed in Investigator-Initiated Phase 1 Trial At University of California Davis Comprehensive Cancer Center

IO Biotech, Inc. Announces Executive Changes

New minor risk - Share price stability

IO Biotech Announces Achievement of Significant Phase 3 Clinical Trial Recruitment Milestone

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

IO Biotech, Inc. Appoints Christine Richter as Senior Vice President, Commercial and Program Lead

Chief Financial Officer recently bought US$58k worth of stock

IO Biotech Appoints Devin Smith as General Counsel and Chief Compliance Officer

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Price target decreased to US$17.50

IO Biotech, Inc. Announces Appointment of Amy Sullivan as Chief Financial Officer

IO Biotech names new CFO

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech GAAP EPS of -$0.64

We're Keeping An Eye On IO Biotech's (NASDAQ:IOBT) Cash Burn Rate

IO Biotech Announces Initiation of Phase 3 Combination Trial of IO102-IO103 and KEYTRUDA® (pembrolizumab) as First-Line Treatment in Advanced Melanoma

IO Biotech, Inc. Announces Executive Changes

High number of new directors

High number of new directors

IO Biotech, Inc. Announces its Two Directors Not Stand for Re-Election

IO Biotech Announces Presentation of New Data from MM1636 Phase 1/2 Clinical Trial Presented at 2022 AACR Annual Meeting

IO Biotech, Inc. Announces Appointment of David V. Smith to Board of Directors

We Think IO Biotech (NASDAQ:IOBT) Needs To Drive Business Growth Carefully

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin